International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all regions and industry verticals to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
Global Monoclonal Antibodies Market Research Report 2023-2028:
According to the latest report by IMARC Group, titled " Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Fore cast 2023-2028
," the global monoclonal antibodies market size reached US$ 207.4 Billion in 2022.
Monoclonal antibodies (mAb) are produced by a single clone of cells or cell lines and consist of identical antibody molecules. These antibodies can have monovalent affinity, binding only to the same epitope. Due to their site-specificity, these serve as essential tools to detect or purify substances. They are being used on a clinical level to diagnose and treat several diseases. They are used as probes to identify materials in laboratories or home-testing kits. Due to their specificity to unique epitopes, monoclonal antibodies are widely used for diagnostic and therapeutic applications for several diseases. Several manufacturers are focusing on creating medications from many classifications to treat various disorders, including cancer and rare diseases. Monoclonal antibodies, in combination with chemotherapeutic drugs, are extensively being used to treat different malignancies.
Request for a PDF sample of this report:
https://www.imarcgroup.com/monoclonal-antibodies-market/requestsample
The global market is majorly driven by the increasing prevalence of chronic diseases, such as cancer and cardiovascular diseases. In line with this, the rising demand for biologics and the growing applications of monoclonal antibodies for targeted therapies are significantly contributing to the market. This is attributed to the escalating awareness about such treatments among patients and physicians. Furthermore, various key players are undertaking strategic initiatives to develop and market mAb products. Apart from this, the heavy investments by top pharmaceutical companies in genomics research and development activities are positively influencing the market.
Moreover, the increasing requirement for effective and affordable therapies for cancer treatment is catalyzing the market. Besides, an extensive product pipeline with potential effective therapies catering to a diverse range of diseases is propelling the market expansion. Additionally, the augmenting focus on the discovery and development of novel monoclonal antibody therapeutics to offer treatment for complex and severe diseases is bolstering the monoclonal antibodies market.
Looking forward, IMARC Group expects the market to reach US$ 307.8 Billion by 2028, exhibiting at a CAGR of 6.9% during 2023-2028.
View Report TOC, Figures and Tables: https://www.imarcgroup.com/monoclonal-antibodies-market
Key Market Segmentation
The research report includes the following segments:
Breakup by Production Method:
• In Vivo
• In Vitro
Breakup by Source:
• Murine
• Chimeric
• Humanized
• Human
Breakup by Indication:
• Cancer
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Others
Breakup by End Use:
• Hospitals
• Research Institutes
• Others
Breakup by Region:
• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa
Competitive Landscape with Key Players:
• AbbVie Inc
• Amgen Inc
• Biogen Inc
• F. Hoffmann-La Roche AG
• GSK plc
• Johnson & Johnson
• Merck KGaA
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc
• Sanofi S.A
• Thermo Fisher Scientific Inc
1. What was the size of the global monoclonal antibodies market in 2022?
2. What is the expected growth rate of the global monoclonal antibodies market during 20232028?
3. What are the key factors driving the global monoclonal antibodies market?
4. What has been the impact of COVID-19 on the global monoclonal antibodies market?
5. What is the breakup of the global monoclonal antibodies market based on the production method?
6. What is the breakup of the global monoclonal antibodies market based on the source?
7. What is the breakup of the global monoclonal antibodies market based on the indication?
8. What is the breakup of the global monoclonal antibodies market based on the end use?
9. What are the key regions in the global monoclonal antibodies market?
10. Who are the key players/companies in the global monoclonal antibodies market?
Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/monoclonal-antibodies-market/toc
We are the trusted business partners to the world's leading corporates, governments, and institutions
We are the trusted business partners to the world's leading corporates, governments, and institutions
© 2022 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
